Log In
Print
BCIQ
Print
Print this Print this
 

VY-FXN01

  Manage Alerts
Collapse Summary General Information
Company Voyager Therapeutics Inc.
DescriptionNot disclosed
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPreclinical
Standard IndicationAtaxia
Indication DetailsTreat Friedreich's ataxia (FRDA)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today